Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor reported 14 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PCVX (32.2%), ARQT (10.6%) and TRVI (9.9%). Compared with Q2 2026, the fund opened new positions in OBX and BRVE, added to OCS, trimmed ARQT, AVLN and ZBIO and sold out of RXRX.
Latest filing: what Pivotal bioVenture Partners Investment Advisor did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PCVX Vaxcyte Inc | $81.1M | 32.2% | 1.4M | No change | 8 of 8 | |
| 2 | ![]() ARQT Arcutis Biotherapeutics Inc | $26.6M | 10.6% | 1M | −257K (−20%) | 8 of 8 | |
| 3 | ![]() TRVI Trevi Therapeutics Inc | $25M | 9.9% | 1.7M | No change | 6 of 8 | |
| 4 | ![]() AVLN Avalyn Pharma Inc | $24.7M | 9.8% | 867K | −100K (−10%) | 2 of 8 | |
| 5 | ![]() EVMN Evommune Inc | $15.9M | 6.3% | 1.9M | No change | 4 of 8 | |
| 6 | ![]() IMNM Immunome Inc | $15.8M | 6.3% | 733K | No change | 5 of 8 | |
| 7 | ![]() OCS Oculis Holding AG | $15.5M | 6.2% | 1.7M | +153K (+10%) | 8 of 8 | |
| 8 | ![]() OBX Obsidian Therapeutics Inc | $11.8M | 4.7% | 860K | New position | 1 of 8 | |
| 9 | ![]() AVTX Avalo Therapeutics Inc | $6.7M | 2.6% | 434K | No change | 3 of 8 | |
| 10 | ![]() BRVE Braveheart Bio Inc | $6.4M | 2.5% | 317K | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() RXRX Recursion Pharmaceuticals in | $2.2M | 596K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Pivotal bioVenture Partners Investment Advisor 13F FAQ
What does Pivotal bioVenture Partners Investment Advisor own?
Pivotal bioVenture Partners Investment Advisor reported 14 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PCVX (32.2%), ARQT (10.6%) and TRVI (9.9%). The table above lists every position in the filing (the top 10 without an account).
What did Pivotal bioVenture Partners Investment Advisor buy and sell in Q3 2026?
Compared with Q2 2026: 2 new positions, 1 added to, 3 trimmed and 1 sold out. New positions include OBX and BRVE. It sold all of RXRX.
When will Pivotal bioVenture Partners Investment Advisor file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Pivotal bioVenture Partners Investment Advisor's portfolio worth?
The Q3 2026 filing reports $252M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.











